SCHEMBL715606

SCHEMBL715606

CC(=O)N1CCCN(c2nc3c(Cl)cccc3cc2C(C)N)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 3/20 0.41
KDM4E B2RXH2 2/20 0.40
ALDH1A1 P00352 1/20 0.40
PIK3CD O00329 4/20 0.40
PDE10A Q9Y233 1/20 0.38
NCF1 P14598 1/20 0.38
MC4R P32245 1/20 0.38
TP53 P04637 2/20 0.37
MAPT P10636 2/20 0.37
CNR1 P21554 2/20 0.37
GRIA1 P42261 1/20 0.37
PDE4A P27815 1/20 0.37
PDE4B Q07343 1/20 0.37
PDE4C Q08493 1/20 0.37
PDE4D Q08499 1/20 0.37
MEN1 O00255 1/20 0.36
THRB P10828 1/20 0.36
PKM P14618 1/20 0.36
CASP1 P29466 1/20 0.36
KLK7 P49862 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL715605 1.00 CNR2 (0.41) CNR2KDM4EALDH1A1PIK3CDPDE10A
SCHEMBL715249 0.86 HPGD (0.43) CNR2KDM4EALDH1A1PIK3CDMAPT
Hydrochloric Acid SCHEMBL721448 0.85 DRD2 (0.40) CNR2ALDH1A1MC4RMAPTPKM
Hydrochloric Acid SCHEMBL17530808 0.85 DRD2 (0.40) CNR2ALDH1A1MC4RMAPTPKM
SCHEMBL714882 0.84 MAPT (0.51) ALDH1A1MC4RTP53MAPTCNR1
SCHEMBL714883 0.84 MAPT (0.51) ALDH1A1MC4RTP53MAPTCNR1
SCHEMBL717259 0.84 PIK3CD (0.53) CNR2KDM4EALDH1A1PIK3CDNCF1
SCHEMBL717258 0.84 PIK3CD (0.53) CNR2KDM4EALDH1A1PIK3CDNCF1
SCHEMBL717269 0.82 PIK3CD (0.41) CNR2KDM4EALDH1A1PIK3CDCNR1
SCHEMBL717268 0.82 PIK3CD (0.41) CNR2KDM4EALDH1A1PIK3CDCNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2403847-B1 TRIAZINE DERIVATIVES AS KINASE INHIBITORS UCB BIOPHARMA SPRL (BE) 2016-03-02 EP disclosed
US-8785628-B2 Triazine derivatives as kinase inhibitors UCB PHARMA, S.A. (BE) 2014-07-22 US disclosed
US-20120053167-A1 Triazine Derivatives as Kinase Inhibitors UCB PHARMA, S.A. (BE) 2012-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053167-A1 Triazine Derivatives as Kinase Inhibitors MAP3K15, PI4KA, MAP3K20 CNR2 1488/4885KDM4E 2430/4885ALDH1A1 3504/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.